Praxis Precision Medicines, Inc.
elsunersen
SCN2A development and epileptic encephalopathy
Resolved
92days ago
Phase 2 readout · Apr 6, 2026
What's at stake
Phase 2 trial results for elsunersen in SCN2A development and epileptic encephalopathy are due Apr 6, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“positive topline results from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study evaluating ascending doses of elsunersen in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.”